Addex Therapeutics Ltd (ADXN) Actualités

Addex to Present at the 2025 Swiss Equities Baader Conference

Geneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND...

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophreniaIndivior...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics...

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex’s Partner Discontinues ADX71149 development in Epilepsy

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and...